In light of NHS boards being expected to fund hybrid closed-loop (HCL) systems for eligible patients in line with NICE and SIGN guidance, w…

As hybrid closed-loop (HCL) systems become embedded within routine diabetes care, funding for their ongoing provision, including £14.4 million for consumable costs, has been incorporated into NHS Board baseline allocations for 2026-27 as part of the wider £17.6 billion allocated to NHS Territorial Boards.NHS Territorial Boards are responsible for planning and delivering services in line with national clinical guidance and local need. On 29 May, Ms Constance wrote to Boards making clear the expectation that funding transferred into baseline allocations should continue to support people with type 1 diabetes using closed-loop systems and seeking assurance that it is being used as intended.To inform future decisions on access, the Scottish Government commissioned the Centre for Sustainable Delivery at NHS Golden Jubilee to examine options for further expansion of HCL systems. This work has been completed and is being considered as part of planning for the 2027-28 Budget.There are currently no plans to establish national targets or timelines for further rollout.